Alflutinib

DRUG3 trials

Sponsors

Allist Pharmaceuticals, Inc.

Conditions

Advanced NSCLCAdvanced NSCLC Patients With T790MNSCLC

Phase 1

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

TerminatedNCT02973763

Allist Pharmaceuticals, Inc.NSCLC

Start: 2016-12-30End: 2023-08-01Updated: 2025-04-03

Phase 2

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

TerminatedNCT03452592

Allist Pharmaceuticals, Inc.Advanced NSCLC Patients With T790M

Start: 2018-04-30End: 2024-03-14Updated: 2025-04-03

Unknown Phase

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

TerminatedNCT03127449

Allist Pharmaceuticals, Inc.Advanced NSCLC

Start: 2017-06-01End: 2024-01-08Updated: 2025-04-03

Related Papers

Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.

2023-04-2815 citations

Progression pattern and post-progression treatment of furmonertinib (AST2818) in EGFR T790M mutation positive NSCLC patients: A post-hoc analysis from a multicenter, single-arm study.

Journal of Clinical Oncology2021-05-201 citations

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.

2021-03-2685 citations

Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.

Journal of Clinical Oncology2020-05-2012 citations

Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation.

2020-01-3078 citations